Provider Preferences on Existing and Potential Future Biomedical HIV Prevention Products: A Qualitative Study in the United States, Thailand, and South Africa
AIDS Research and Human Retroviruses · 2026
DOI: 10.1177/08892229261480775 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift AIDS Research and Human Retroviruses, 2026. Verfasst von Christine Tagliaferri Rael und 14 weiteren Autor:innen. Beteiligte Einrichtung: College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Anti-HIV Agents, Health Personnel. Die Arbeit nennt 67 Literaturangaben. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Several forms of HIV pre-exposure prophylaxis (PrEP) are approved, prescribed off-label, or in development in the United States, including daily oral tablets, long-acting injectable cabotegravir (CAB-LA), removable implants, and rectal tenofovir products. To understand how health care providers prioritize among these options, 30 providers from the United States, Thailand, and South Africa completed online surveys, and 10 participated in in-depth interviews. Providers shared their perspectives on current and emerging PrEP products, key informational needs for gay and bisexual men, and preferred educational strategies. When asked to rank PrEP options if all were simultaneously available, providers most often prioritized removable implants ( N = 3), daily oral PrEP ( N = 3), CAB-LA ( N = 1), and rectal douches/enemas ( N = 1), while others ( N = 2) emphasized patient preference. Overall, providers noted that each product has unique advantages and expressed support for digital shared decision-making tools to enhance patient–provider communication about PrEP selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Columbia University Mailman School of Public Health, New York, New York, USA.
- College of Medicine, Florida State University, Tallahassee, Florida, USA.
- Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Florida, USA.
- HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, New York, USA.
- Department Of English, Baruch College, New York, New York, USA.
ORCID-Profile: Christine Tagliaferri Rael
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Tagliaferri Rael, C., Das, D., Giguere, R., Porter, J., Bryndza Tfaily, E., Tuswa Haynes, C., Ho, T., McKenna, S., Lopez-Ríos, J., Lentz, C., Dolezal, C., Stonbraker, S., Hendrix, C., D'Aquila, R. T., & Hope, T. J. (2026). Provider Preferences on Existing and Potential Future Biomedical HIV Prevention Products: A Qualitative Study in the United States, Thailand, and South Africa. AIDS Research and Human Retroviruses. https://doi.org/10.1177/08892229261480775
Vancouver
Tagliaferri Rael C, Das D, Giguere R, Porter J, Bryndza Tfaily E, Tuswa Haynes C, et al. Provider Preferences on Existing and Potential Future Biomedical HIV Prevention Products: A Qualitative Study in the United States, Thailand, and South Africa. AIDS Research and Human Retroviruses. 2026. doi:10.1177/08892229261480775
BibTeX
@article{TagliaferriRael2026,
author = {Tagliaferri Rael, Christine and Das, Doyel and Giguere, Rebecca and Porter, Jonathan and Bryndza Tfaily, Ewa and Tuswa Haynes, Camagu and Ho, Titcha and McKenna, Stacey and Lopez-Ríos, Javier and Lentz, Cody and Dolezal, Curtis and Stonbraker, Samantha and Hendrix, Craig and D'Aquila, Richard T and Hope, Thomas J},
title = {Provider Preferences on Existing and Potential Future Biomedical HIV Prevention Products: A Qualitative Study in the United States, Thailand, and South Africa},
journal = {AIDS Research and Human Retroviruses},
year = {2026},
doi = {10.1177/08892229261480775}
}
EUVIMED